Accuracy of post–neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer

MK Tasoulis, HB Lee, W Yang, R Pope… - JAMA …, 2020 - jamanetwork.com
Importance Image-guided breast biopsy of a residual imaging abnormality or tumor bed after
neoadjuvant chemotherapy (NACT) is increasingly used to assess residual cancer, facilitate …

Omission of breast surgery in exceptional responders

MK Tasoulis, HB Lee, HM Kuerer - Clinical breast cancer, 2024 - Elsevier
Breast cancer management has transformed significantly over the last decades, primarily
through the integration of neoadjuvant systemic therapy (NST) and the evolving …

Oncoplastic and reconstructive breast surgery

P Wignarajah, CM Malata, JR Benson - Frontiers in Oncology, 2023 - frontiersin.org
This article provides an overview of the principles and techniques of oncoplastic and
reconstructive breast surgery for patients with early-stage breast cancer. Oncoplastic breast …

MiR-195 and its target SEMA6D regulate chemoresponse in breast cancer

DE Baxter, LM Allinson, WS Al Amri, JA Poulter… - Cancers, 2021 - mdpi.com
Simple Summary The resistance of cancer cells to cytotoxic chemotherapy limits cure rates
in breast cancer, and a better understanding of resistance mechanisms will aid design of …

Nipple-sparing mastectomy after neoadjuvant chemotherapy: definitive results with a long-term follow-up evaluation

E Zarba Meli, A De Santis, G Cortese, E Manna… - Annals of Surgical …, 2023 - Springer
Background Nipple-sparing mastectomy (NSM) is increasingly used for women with breast
cancer who are not candidates for conservative surgery. The authors previously reported …

[HTML][HTML] Neoadjuvant approach in patients with early breast cancer: Patient assessment, staging, and planning

IT Rubio, C Sobrido - The Breast, 2022 - Elsevier
Neoadjuvant treatment (NAT) has become an option in early stage (stage I-II) breast cancer
(EBC). New advances in systemic and targeted therapies have increased rates of pathologic …

Clinical outcomes among major breast cancer subtypes after neoadjuvant chemotherapy: Impact on breast cancer recurrence and survival

P Orsaria, A Grasso, E Ippolito, F Pantano… - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: Prior studies have underlined the prognostic relevance of pathological
complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer …

[HTML][HTML] Рак молочной железы

ЛГ Жукова, ЮЮ Андреева… - Современная …, 2021 - cyberleninka.ru
Рак молочной железы (РМЖ)-злокачественная опухоль, исходящая из эпителия ткани
молочной железы. Не существует единого этиологического фактора развития РМЖ. У …

Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study

RV Dave, B Elsberger, VP Taxiarchi, A Gandhi… - Breast Cancer Research …, 2023 - Springer
Abstract Purpose The B-MaP-C study investigated changes to breast cancer care that were
necessitated by the COVID-19 pandemic. Here we present a follow-up analysis of those …

[HTML][HTML] Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study

Y Chen, X Liu, K Yu, X Sun, S Xu, P Qiu… - Annals of …, 2022 - ncbi.nlm.nih.gov
Background The discordance of estrogen receptor (ER), progesterone receptor (PR), human
epidermal growth factor receptor 2 (HER2), and Ki-67 cell nuclear proliferation antigen …